Genelux (GNLX) Q4 2024 earnings summary

Executive summary

• Achieved alignment with FDA on approval pathway for Olvi-Vec in platinum-resistant/refractory ovarian cancer, potentially avoiding a separate confirmatory study.

• Reported positive preliminary Phase 1b/2 data for Olvi-Vec in advanced small-cell lung cancer, showing promising disease control and tumor reduction.

• Strengthened management with the appointment of a new CFO and bolstered balance sheet through a $10.5 million underwritten stock offering.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $30.9 million as of December 31, 2024, providing runway into Q1 2026.

• Research and development expenses increased to $19.0 million in 2024 from $12.8 million in 2023, mainly due to higher clinical trial costs and new hires.

• General and administrative expenses rose to $12.7 million in 2024 from $11.6 million in 2023, driven by higher compensation, stock expenses, and consulting costs.

• Net loss was $29.9 million ($0.95 per share) for 2024, compared to $28.3 million ($1.16 per share) in 2023.

• Revenues were minimal at $8,000 in 2024, down from $170,000 in 2023.

Outlook and guidance

• Topline data from the pivotal Phase 3 OnPrime/GOG-3076 trial in ovarian cancer expected in the first half of 2026.

• Interim results from ongoing lung cancer trials anticipated in the second half of 2025.

• Cash position expected to fund operations into the first quarter of 2026.